Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADP-1 is a postbiotic ingredient, specifically an inactivated form of the probiotic bacteria *Lactobacillus paracasei*. Developed by USANA Health Sciences, it is incorporated into oral care products, such as toothpaste, to promote oral health. Its mechanism of action involves inhibiting the adhesion of caries-causing bacteria, preventing dental plaque formation, and reducing the growth of *Streptococcus mutans*. ADP-1 also works to balance the oral microbiome and lower inflammation to protect gums, contributing to overall oral hygiene and a longer-lasting clean.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADP-1.